Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors

The purpose of this study is to test the manufacturing feasibility and safety of intravenous (IV) administration of B7-H3CART in children and young adult subjects with relapsed and/or refractory solid tumors expressing B7-H3 target using a standard 3+3 dose escalation design.

Trial Details

NCT ID

NCT06500819

Phase

PHASE1

Sponsor

Stanford University

Status

RECRUITING

Cancer Type

Osteosarcoma Sarcoma

Interventions

B7-H3CART Dose (Intravenous)

Locations (sample)

Palo Alto, California, United States|37.44188,-122.14302

Key Eligibility Criteria

Histologically confirmed malignant solid tumor (including neuroblastoma, soft tissue sarcoma, osteosarcoma, Ewing Sarcoma, and Wilms tumor) with ev…
Subjects with neuroblastoma must have received or be intolerant to anti-GD2 antibody therapy.
Subjects with Wilm's tumor must have received or be intolerant to ifosfamide or cyclophosphamide plus etoposide therapy or alternative salvage regi…
Subjects with embryonal rhabdomyosarcoma must have received or be intolerant to Adriamycin-based therapy.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Osteosarcoma Sarcoma Trials on Trialify →